JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.
This publication reviews the current landscape of JAK inhibitors in the treatment of myelofibrosis, a myeloproliferative...
Radiotherapy alone versus combined therapy in stage I natural killer/T-cell lymphoma: impact of local invasion on treatment outcomes.
- Post category:Hematologic Cancers
- Reading time:1 min read
This retrospective study analyzed 294 stage I natural killer/T-cell lymphoma (NKTCL) patients treated with radiation the...
Combining radiotherapy and immune checkpoint inhibitors in metastatic cancers: a 25-year review of safety outcomes by the ENRSO Group.
- Post category:Hematologic Cancers
- Reading time:1 min read
This scoping review systematically examined the safety and feasibility of combining immune checkpoint inhibitors (ICIs)...
An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study addresses a key limitation in CRISPR/Cas9 gene knockout research within cancer immunology, where persistent e...
A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors.
- Post category:Hematologic Cancers
- Reading time:1 min read
This retrospective cohort study of 6,526 adult cancer patients treated with immune checkpoint inhibitors (ICIs) between...
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
- Post category:Hematologic Cancers
- Reading time:1 min read
This multicenter retrospective study evaluated talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, in 114 heav...